Trial Profile
A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Choroid plexus cell replacement therapy (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Living Cell Technologies
- 12 May 2019 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 1 Oct 2017 to 1 Apr 2019.
- 21 Dec 2017 The 26 week results of this trial require further analysis and patients will continue to be monitored in accordance with the study extension protocol, as reported in a Living Cell Technologies media release.